Optimizing Quviviq Prior Authorization Workflows for Gastroenterology

The Prior Authorization Imperative for Medications in Gastroenterology

Gastroenterology practices frequently navigate prior authorization for a broad spectrum of treatments, from high-cost biologics for IBD to advanced diagnostic imaging and specialty drugs. Medications like Quviviq, which are subject to prior authorization across various payer types, add to this administrative load. Klivira provides a robust solution to manage these diverse PA requirements efficiently, ensuring that patient access is not hindered by manual processing.

Key Prior Authorization Complexities in GI

• Ongoing PA burden for chronic treatments, such as IBD biologics, requiring periodic re-authorization and continuous documentation of disease response.
• Variability in biosimilar substitution policies across different payers for TNF inhibitors and other biologics.
• Precise classification of treatment-naive vs. treatment-experienced patients, critical for both IBD biologics and Hepatitis C DAAs.
• Navigating the medical vs. pharmacy benefit split for biologic agents, which can shift based on administration mode.
• Meeting specific documentation requirements for advanced imaging (e.g., MRCP, MR enterography) and endoscopic procedures (e.g., capsule endoscopy).

Klivira's Strategic Approach to Prior Authorization in Gastroenterology

Klivira's platform is engineered to address the inherent complexities of prior authorization within gastroenterology. By integrating directly with EMRs and payer portals, we automate the submission and tracking process for all PA-requiring services and medications, including high-volume drugs like Quviviq. This ensures that GI practices can maintain focus on patient care while accelerating approval times.

Klivira Capabilities for GI Prior Authorization

• ACG and AGA guideline-aware step therapy logic, automating sequencing for IBD biologics.
• Automated classification of patient treatment status (naive vs. experienced) based on EMR medication history.
• Structured workflows for Hepatitis C DAA submissions, incorporating genotype, fibrosis stage, and drug-interaction documentation.
• Proactive management of periodic re-authorization cycles for chronic GI therapies.
• Intelligent routing for medical vs. pharmacy benefit claims, adapting to changes in biologic agent administration.

Optimizing Documentation and Mitigating Denials for GI Therapies

Accurate and complete documentation is paramount for prior authorization approval in gastroenterology. Klivira streamlines the collection and submission of critical data points, such as disease severity scores (Mayo score, CDAI), prior conventional therapy trials, and essential screenings (TB, hepatitis). This proactive approach significantly reduces common denial reasons, including step therapy non-compliance or insufficient clinical detail, improving the first-pass approval rate for all PA-requiring treatments, including Quviviq.

Seamless EMR Integration for GI Workflows

Klivira leverages SMART on FHIR capabilities to integrate directly with leading EMR systems, ensuring that clinical data required for prior authorization is pulled efficiently and accurately. This eliminates manual data entry, minimizes errors, and ensures that all necessary patient information, from diagnostic findings to medication history, is readily available for X12 278 and ePA submissions.